Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine

OBJECTIVE: Evaluate the safety and tolerability of oral rimegepant when used for acute treatment concomitantly with a monoclonal antibody (mAb) targeting the calcitonin gene‐related peptide (CGRP) ligand or receptor (CGRP mAb) for the preventive treatment of migraine. BACKGROUND: The efficacy of CGR...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Headache
Hlavní autoři: Berman, Gary, Croop, Robert, Kudrow, David, Halverson, Philip, Lovegren, Meghan, Thiry, Alexandra C., Conway, Charles M., Coric, Vladimir, Lipton, Richard B.
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2020
Témata:
Research Submissions
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7496574/
https://ncbi.nlm.nih.gov/pubmed/32799325
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/head.13930
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky